

Supplement
dated 12 January 2021

to the Base Prospectus for
Constant Leverage Certificates
dated 10 June 2020



Supplement

dated 12 January 2021

to the **Base Prospectus for
Constant Leverage Certificates**

dated 10 June 2020

Vontobel Financial Products GmbH

Frankfurt am Main, Germany

(the "**Issuer**")

Bank Vontobel Europe AG

Munich, Germany

(in its capacity as offeror, the "**Offeror**" and
in its capacity as guarantor, the "**German Guarantor**", as the case may be)

Vontobel Holding AG

Zurich, Switzerland

(the "**Swiss Guarantor**", as the case may be;
the Swiss Guarantor and the German Guarantor together the "**Guarantors**" and each a "**Guarantor**")

Investors who have already agreed to purchase or subscribe for the securities before the supplement is published shall have the right according to Article 23 paragraph 2 sentence 1 of the Regulation (EU) 2017/1129 dated 14 June 2017 as amended from time to time (the "**Prospectus Regulation**"), exercisable within two working days after the publication of the supplement, to withdraw their acceptances, provided that the significant new factor, material mistake or material inaccuracy referred to in Article 23 paragraph 1 of the Prospectus Regulation arose or was noted before the closing of the offer period or the delivery of the securities, whichever occurs first.

Statement concerning the right of withdrawal

A right of withdrawal is only granted to those investors who had already agreed to purchase or subscribe for the securities before the supplement was published and where the securities had not yet been delivered to the investors at the time when the significant new factor, material mistake or material inaccuracy arose or was noted.

Investors can exercise their right of withdrawal within two working days after the publication of the supplement.

Investors must contact the Issuer (Vontobel Financial Products GmbH, Bockenheimer Landstraße 24, 60323 Frankfurt am Main, Germany; email: vfp-frankfurt@vontobel.com) should they wish to exercise the right of withdrawal.

This supplement dated 12 January 2021 (the "**Supplement**") as well as the Base Prospectus for Constant Leverage Certificates dated 10 June 2020 (the "**Base Prospectus**") are accessible by entry of the respective ISIN on the website prospectus.vontobel.com. In addition, the Issuer will have copies of the Supplement and the Base Prospectus available free of charge.

Table of contents

1. Reason for the Supplement	5
2. Amendments to the Base Prospectus	6
<hr/>	

1. Reasons for the Supplement

The Issuer announces the following new factors relating to the information included in the Base Prospectus:

- 1) The share of Teladoc Health Inc. should be available as a new Reference Instrument for Factor Indices linked to shares, securities representing shares and other dividend-bearing securities. This new factor occurred on 12 January 2021.
- 2) The share of CRISPR Therapeutics AG should be available as a new Reference Instrument for Factor Indices linked to shares, securities representing shares and other dividend-bearing securities. This new factor occurred on 12 January 2021.

2. Amendments to the Base Prospectus

As a result of the reason for the Supplement mentioned under section 1., the Base Prospectus shall be amended as follows:

In section 8.1.2 Reference Instrument List (shares, securities representing shares and other dividend-bearing securities) of the Base Prospectus, the following lines are added to the table on page 80 of the Base Prospectus.

NAME	TYPE	CURRENCY	COMPANY	ISIN	BLOOMBERG	REFERENCE EX-CHANGE	DERIVATIVES EXCHANGE
Teladoc Health Inc.	Registered Share	USD	CRISPR Therapeutics AG, Aeschenvorstadt 36, Basel, CH-4051, Switzerland	CH0334081137	CRSP UQ	XNMS	Nasdaq Global Market
CRISPR Therapeutics AG	Registered Share	USD	Teladoc Health Inc., 2 Manhattanville Road, Suite 203, Purchase, NY 10577, United States	US87918A1051	TDOC UN	XNYS	NYSE